| __timestamp | Halozyme Therapeutics, Inc. | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 79696000 | 14182353 |
| Thursday, January 1, 2015 | 93236000 | 15503028 |
| Friday, January 1, 2016 | 150842000 | 16183585 |
| Sunday, January 1, 2017 | 150643000 | 22382849 |
| Monday, January 1, 2018 | 150252000 | 33038206 |
| Tuesday, January 1, 2019 | 140804000 | 31777040 |
| Wednesday, January 1, 2020 | 34236000 | 41464134 |
| Friday, January 1, 2021 | 35672000 | 67178053 |
| Saturday, January 1, 2022 | 66607000 | 52531000 |
| Sunday, January 1, 2023 | 76363000 | 68914000 |
| Monday, January 1, 2024 | 79048000 |
Unlocking the unknown
In the ever-evolving world of biotechnology, research and development (R&D) is the lifeblood of innovation. Over the past decade, Halozyme Therapeutics, Inc. and Pharming Group N.V. have demonstrated contrasting R&D investment strategies. Halozyme's R&D expenses peaked in 2016, with a notable 50% increase from 2014, before experiencing a decline in subsequent years. In contrast, Pharming Group N.V. has shown a steady upward trajectory, with R&D spending more than quadrupling from 2014 to 2023. This divergence highlights the strategic differences between the two companies: while Halozyme may have focused on optimizing existing technologies, Pharming appears to be ramping up its innovation pipeline. As we look to the future, these trends offer a glimpse into the strategic priorities shaping the biotech landscape.
Eli Lilly and Company or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc.
Research and Development Investment: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and MannKind Corporation
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
Research and Development Investment: Pharming Group N.V. vs Alkermes plc
R&D Insights: How Pharming Group N.V. and MannKind Corporation Allocate Funds
R&D Spending Showdown: Pharming Group N.V. vs Dynavax Technologies Corporation